Skip to main content
Lab technicians in Kankakee)

R&D Capabilities

Excellence in Research & Development

CSL Behring's mission is to discover, develop, and deliver our innovative therapies that improve the patients' quality of life. Our scientists and researchers are recognized for their contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.

We are grateful to the patients, volunteers, and researchers that participate in the clinical trials for testing our potential biotherapies. All contributions have helped better our understanding of diseases.

CSL Behring's R&D capabilities are focused in three major areas:

close up image of product bottles

Plasma Fractionation

CSL Behring’s clinical research activities make products available to patients worldwide and identify novel therapeutic uses for plasma proteins.

As a leading manufacturer and developer of therapeutics derived from human plasma, CSL Behring is committed to maintaining the highest product safety standards and to continually improving manufacturing effectiveness. CSL Behring's research programs are focused on developing novel plasma proteins with improved efficacy and enhanced convenience.

image of a scientist filling a vial

Recombinant Technology

We have extensive experience in the production, clinical development and launch of recombinant coagulation factors.

We are also focused on the development, production and testing of novel monoclonal antibodies (mAbs) to treat inflammatory diseases (CSL324), hereditary angioedema (CSL312) and target fatty acid metabolism (CSL346).
In collaboration with Momenta Pharmaceuticals, we are also developing recombinant Fc multimer proteins to control inflammation associated with autoimmune diseases.

3D Visualisation of DNA

Gene and Cell Therapy

Through the acquisition of Calimmune Inc., CSL is focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy which has the potential to offer a significant advantage to patients suffering from currently incurable genetic diseases.

Cell and gene therapies are highly innovative, next-generation products that, after decades of research and development, are now starting to positively impact the lives of patients with serious diseases. For diseases with few effective therapeutic options, such as certain blood cell cancers, or where successful therapy has required a lifetime of regular symptomatic treatment, such as rare inherited genetic deficiencies, they offer the promise of a long-term cure.

The technology has the potential to be used in treatments for a wide range of rare diseases that would complement our business, including those within the company’s current product portfolio.

R&D Capabilities

These capabilities manifest themselves in the following therapeutic areas:

Woman with microscope


Our world-leading immunoglobulin (Ig) franchise is the cornerstone of the immunology therapeutic area. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a range of serious immunologic and neurologic diseases, including Primary and Secondary Immunodeficiencies (PID and SID) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). We are optimizing patient experience and convenience through more flexible ways to dose and administer our existing intravenous and subcutaneous plasma-derived products.

Hand holding a pipet


CSL Behring remains focused on easing the burden of care and improving the lives of patients with rare bleeding disorders. We are undertaking exciting research and development efforts to explore new indications in hematology as well as novel therapeutics in hemostasis and thrombosis. Our hemophilia research strategy is based on maximizing the value and performance of our existing coagulation therapies and developing new protein-based therapies to treat bleeding disorders and increase the quality of life for patients.

Transplant surgeon


Despite the remarkable advances in solid organ transplantation reflected by improved patient and graft survival rates, the treatment and management of solid organ transplant recipients remains a complex area of modern medicine. Organ transplant recipients are required to take life-long immunosuppressive medication to prevent their own immune systems from rejecting the donor organ (allograft). While current standard of care is very effective in the prevention and treatment of acute rejection, chronic rejection remains a high unmet medical need and is responsible for most cases of allograft failure. 

healthcare professionals


Chronic respiratory diseases impose an enormous burden on patients and society and are a leading cause of death and disability worldwide. To address this need, CSL is investigating new clinical treatments for respiratory diseases using our plasma derived immunoglobulins and proteins and novel recombinant monoclonal antibodies. 

photo of gloved employees handling many product bottles

Cardiovascular and Metabolic

The cardiovascular and metabolic therapeutic area is focused on improving and extending the lives of patients with cardiovascular disease (CVD) and diabetes.